Johnson & Johnson reported Q2 2026 sales of $25.3 billion and adjusted EPS of $2.90, beating expectations with strong operational performance. The company increased its full-year sales forecast to $101.1 billion and adjusted EPS guidance, setting a goal for record annual revenue.